Adult Bacterial Pneumonia Drug Treatment Mechanism of Action Showcase

This next-generation pleuromutilin antibacterial is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP). This new drug is a systemic, empiric pleuromutilin antibiotic with activity against specific Gram-positive, Gram-negative, and other respiratory bacteria. It has a a chemical structure distinct from existing classes of antibiotics used in CABP and adverse reactions were generally mild to moderate regardless of how it was administered (oral or IV). This stunning animation highlights ground-breaking technology that can be used for marketing and education.